Fill Finish Manufacturing Global Market Report 2024

The fill finish manufacturing market size has grown rapidly in recent years. It will grow from $10 billion in 2023 to $11.08 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The increase observed in the historical period can be ascribed to the growth of the biopharmaceutical industry, the expansion of contract manufacturing organizations (CMOs), a surge in drug approval and development, a heightened demand for parenteral medications, and an augmented prevalence of chronic diseases.

The fill finish manufacturing market size is expected to see rapid growth in the next few years. It will grow to $16.91 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The anticipated expansion in the forecast period can be credited to the increase in contract manufacturing, a focus on regulatory compliance and serialization, sustainability and green initiatives, a growing demand for ready-to-use solutions, and the emergence of new therapeutic modalities. Key trends expected in the forecast period involve the adoption of single-use systems, advancements in aseptic technologies, the implementation of remote monitoring and control systems, partnerships for technology advancements, and an increased demand for lyophilization.

The anticipated surge in demand for pharmaceutical products is set to drive the growth of the fill-finish manufacturing market in the future. Pharmaceutical products encompass substances or compounds formulated and manufactured for the prevention, diagnosis, or treatment of medical conditions. Fill-finish manufacturing, a pivotal process in the pharmaceutical industry, specifically caters to the production of pharmaceutical products. This process involves the final stages of manufacturing, where the pharmaceutical product is filled into its ultimate container, such as vials, syringes, bottles, or blister packs, and is then completed with labeling and packaging. For instance, in February 2023, reports from Merck & Co., Inc., a Germany-based pharmaceutical company, revealed worldwide pharmaceutical product sales of $59.3 billion in 2022, marking a 22% increase from full-year 2021. Additionally, according to the European Federation of Pharmaceutical Industries and Associations, a Belgium-based lobbying organization, in 2020, US pharmaceutical sales constituted 49.0% of global revenues, compared to Europe's 23.9%. Therefore, the growing demand for pharmaceutical products is steering the growth of the fill-finish manufacturing market.

The increasing need for personalized medicine is also expected to contribute to the growth of the fill-finish manufacturing market. Personalized medicine involves an innovative approach to medical treatment and healthcare that takes into account individual variations in patients' genes, environments, and lifestyles. Fill-finish manufacturing plays a crucial role in producing personalized medicine, facilitating the final stages of drug manufacturing and preparing for distribution. In 2022, according to The Personalized Medicine Coalition, a US-based non-profit organization, personalized medicines accounted for 35% of newly approved new molecular entities (NMEs) in 2021. Therefore, the rising demand for personalized medicine is propelling the growth of the fill-finish manufacturing market in the future.


Product innovation stands out as a prominent trend gaining traction in the fill-finish manufacturing market. Leading companies within the market are actively engaged in the development of innovative products to maintain their competitive positions. For instance, SGD Pharma, a pharmaceutical primary glass packaging manufacturer based in France, introduced its Ready-to-Use (RTU) sterile 100-ml molded glass vials with SG EZ-fill packaging technology in March 2022. This novel product, available in both clear and amber molded glass, caters to the needs of drug manufacturers seeking a high-quality, cost-effective, and reliable RTU solution for injectable drugs. Notably, its unique tray design streamlines the vial-washing, depyrogenation, and sterilization processes in a single step, eliminating the need for manual intervention and reducing contamination risks.

Major players in the fill-finish manufacturing market are directing their efforts toward the development of innovative systems, exemplified by vial fill/finish systems. These specialized manufacturing systems are designed for the final stages of pharmaceutical production, focusing on filling drug products into vials and preparing them for distribution. An illustrative example is Watson-Marlow Fluid Technology Solutions (WMFTS), a US-based manufacturer of niche peristaltic pumps, which introduced Cellefill in May 2023. Cellefill, a vial fill/finish system with an integrated barrier solution, adheres to Good Manufacturing Practices (GMP) and is specifically designed to offer enhanced process flexibility for the production of Advanced Therapy Medicinal Products (ATMPs) and biologic therapies.

In February 2021, Cytiva, a US-based provider of bioprocessing products and services for the biopharmaceutical industry, acquired Vanrx Pharmasystems Inc. for an undisclosed amount. This acquisition positions Cytiva to better serve its customers, expedite therapy delivery to patients, and strengthen its presence in the biopharmaceutical manufacturing market. Vanrx Pharmasystems Inc., headquartered in Canada, specializes in developing aseptic filling machines for the pharmaceutical industry, facilitating the injection of drugs into nested vials, syringes, or cartridges.

Major companies operating in the fill finish manufacturing market report are Johnson And Johnson, AbbVie Inc., Thermo Fisher Scientific Inc., Becton Dickinson And Company, Baxter International Inc., Lonza Group Ltd., Catalent Inc., Optima Packaging Group GmbH, West Pharmaceutical Services Inc., Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Piramal Pharma Solutions, Siegfried Holding AG, Recipharm AB, Stevanato Group, Boehringer Ingelheim BioXcellence, SCHOTT Pharma, Aenova Group, Curia Global Inc., Groninger And Co GmbH, SGD Pharma, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Rentschler Biopharma SE, Cerbios-Pharma SA, Nipro Corporation, Maquinaria Industrial Dara SL.

North America was the largest region in the fill finish manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fill finish manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fill finish manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of products within fill-finish manufacturing are consumables and instruments. Consumable products are those designed to be used up or depleted after a specific period of time or usage. This category encompasses various modalities, including recombinant proteins, monoclonal antibodies, vaccines, cell therapies, viral gene therapies, non-viral gene therapies, and others. The primary end-users include contract manufacturing organizations, biopharmaceutical companies, and others.

The fill-finish manufacturing market research report is one of a series of new reports that provides fill-finish manufacturing market statistics, including fill-finish manufacturing industry global market size, regional shares, competitors with a fill-finish manufacturing market share, detailed fill-finish manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the fill-finish manufacturing industry. This fill-finish manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fill finish manufacturing market includes revenues earned by entities by providing services such as formulation, filling, aseptic processing, capping, labeling, packing, and quality assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. The fill-finish manufacturing market also includes sales of pre-filled syringes, vials, cartridges, vaccines, and ophthalmic and inhalation products. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.